Sobi’s Sanofi-partnered Altuvoct (efanesoctocog alfa) has been recommended by the National Institute for Health and Care ...

Discover how health economics can support successful Medical Device launch, proposition development, and market access. Join ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Galderma’s Nemluvio (nemolizumab) to treat both ...

Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, ...

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year ...

Real-time payments: US respondents place slightly higher importance on speed of payment to participants (87% US sites and 81% ...

Around the world, events are being held to mark Rare Disease Day (28 February 2025), with the aim of bringing attention to ...

Eli Lilly has unveiled plans to invest at least $27bn in building four new pharmaceutical manufacturing sites in the US.

To deliver treatments for rare diseases more quickly, companies share how they are adapting their launch strategies and ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

A study led by Queen Mary University of London has found 69 previously unidentified genetic determinants of rare diseases.